Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

Summary by MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company

1 Articles

MarketBeatMarketBeat
Center

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Friday, October 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Foster City icon

Foster City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal